Status:

COMPLETED

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions:

Exocrine Pancreatic Insufficiency

Steatorrhea

Eligibility:

All Genders

7-60 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of e...

Detailed Description

This is a randomized, placebo-controlled, double-blind withdrawal, multicenter study to evaluate the effectiveness of pancrelipase MT capsules compared with placebo in the treatment of adult (\>18 to ...

Eligibility Criteria

Inclusion

  • Have a diagnosis of CF documented by sweat chloride results (\>60 mmol/L) and require pancreatic enzyme replacement therapy (PERT) to control clinical symptoms of EPI (nausea, vomiting, bloating, diarrhea, and abdominal pain) with a history of excess fat in the feces
  • Have documentation of an abnormal COA-fat and a fecal elastase result of \<100 micrograms fecal elastase/gram stool
  • Must be on a stable diet and dose of pancreatic enzyme supplementation that has provided satisfactory symptom control for at least the past 1 month

Exclusion

  • No extreme physical wasting with loss of weight and muscle mass
  • No severe, acute, or chronic pulmonary disease unrelated to complications of CF
  • No worsening of pulmonary disease in past 30 days
  • No use of drugs known to affect blood uric acid concentrations (e.g., aspirin, diflunisal, allopurinol, probenecid, thiazide diuretics, phenylbutazone, sulfinpyrazone)
  • No known congenital (present at birth) abnormalities of the gastrointestinal tract, heart, or liver
  • No distal intestinal obstruction syndrome (DIOS)

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00662675

Start Date

August 1 2008

End Date

February 1 2009

Last Update

May 9 2014

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Long Beach, California, United States

2

Los Angeles, California, United States

3

Orlando, Florida, United States

4

Louisville, Kentucky, United States